GH Research Shares Jump After Positive Phase 2B Trial Results

Dow Jones02-03 22:58

By Chris Wack

GH Research shares were up 801 to $19.15 after the company said the primary endpoint was met in a Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with treatment-resistant depression.

The Dublin-based biopharmaceutical company said the trial recruited 81 patients with TRD, with 40 patients receiving GH001 and 41 receiving placebo.

Psychotherapeutic intervention wasn't a component of either part of this trial, said the company.

GH said GH001 led to a significant reduction of patients on the Montgomery-Asberg Depression Rating Scale compared with the placebo group.

All secondary endpoints in the trial were met, with results consistent with the primary endpoint, the company said.

GH001 was well-tolerated and no serious adverse events were reported in the double-blind part of the trial, and all treatment emergent adverse events were mild or moderate with no severe adverse events observed, said GH. There was no evidence of treatment-emergent suicidal ideation or behavior after treatment with GH001, the company said.

As of Jan. 22, nine patients are ongoing, 54 patients have completed and 18 patients have discontinued early, added GH.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

February 03, 2025 09:58 ET (14:58 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2508144212?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-03 22:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2508144212","market":"nz","top_or_hot":-1,"title":"GH Research Shares Jump After Positive Phase 2B Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  GH Research shares were up 801 to $19.15 after the company said the primary endpoint was met in a Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with treatment-resistant depression. \n</p>\n<p>\n  The Dublin-based biopharmaceutical company said the trial recruited 81 patients with TRD, with 40 patients receiving GH001 and 41 receiving placebo. \n</p>\n<p>\n  Psychotherapeutic intervention wasn't a component of either part of this trial, said the company. \n</p>\n<p>\n  GH said GH001 led to a significant reduction of patients on the Montgomery-Asberg Depression Rating Scale compared with the placebo group. \n</p>\n<p>\n  All secondary endpoints in the trial were met, with results consistent with the primary endpoint, the company said. \n</p>\n<p>\n  GH001 was well-tolerated and no serious adverse events were reported in the double-blind part of the trial, and all treatment emergent adverse events were mild or moderate with no severe adverse events observed, said GH. There was no evidence of treatment-emergent suicidal ideation or behavior after treatment with GH001, the company said. \n</p>\n<p>\n  As of Jan. 22, nine patients are ongoing, 54 patients have completed and 18 patients have discontinued early, added GH. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 03, 2025 09:58 ET (14:58 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research Shares Jump After Positive Phase 2B Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research Shares Jump After Positive Phase 2B Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-03 22:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Chris Wack \n\n\n \n\n\n  GH Research shares were up 801 to $19.15 after the company said the primary endpoint was met in a Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate,...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GHRS","symbol_name":"GH Research PLC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2508144212","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508144212","pubTimestamp":1738594680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"GH Research shares were up 801 to $19.15 after the company said the primary endpoint was met in a Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with treatment-resistant depression.The Dublin-based biopharmaceutical company said the trial recruited 81 patients with TRD, with 40 patients receiving GH001 and 41 receiving placebo.Psychotherapeutic intervention wasn't a component of either part of this trial, said the company.GH said GH001 led to a significant reduction of patients on the Montgomery-Asberg Depression Rating Scale compared with the placebo group.All secondary endpoints in the trial were met, with results consistent with the primary endpoint, the company said.GH001 was well-tolerated and no serious adverse events were reported in the double-blind part of the trial, and all treatment emergent adverse events were mild or moderate with no severe adverse events observed, said GH. There was no evidence of treatment-emergent suicidal id","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GHRS":"GH Research PLC","BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","BK4585":"ETF&股票定投概念","GH":"Guardant Health Inc.","BK4588":"碎股","BK4539":"次新股","BK4007":"制药","BK4196":"保健护理服务"},"translate_title":"GH Research股价在2B期试验结果积极后上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1,"GHRS":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  GH Research shares were up 801 to $19.15 after the company said the primary endpoint was met in a Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with treatment-resistant depression. \n\n\n  The Dublin-based biopharmaceutical company said the trial recruited 81 patients with TRD, with 40 patients receiving GH001 and 41 receiving placebo. \n\n\n  Psychotherapeutic intervention wasn't a component of either part of this trial, said the company. \n\n\n  GH said GH001 led to a significant reduction of patients on the Montgomery-Asberg Depression Rating Scale compared with the placebo group. \n\n\n  All secondary endpoints in the trial were met, with results consistent with the primary endpoint, the company said. \n\n\n  GH001 was well-tolerated and no serious adverse events were reported in the double-blind part of the trial, and all treatment emergent adverse events were mild or moderate with no severe adverse events observed, said GH. There was no evidence of treatment-emergent suicidal ideation or behavior after treatment with GH001, the company said. \n\n\n  As of Jan. 22, nine patients are ongoing, 54 patients have completed and 18 patients have discontinued early, added GH. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 03, 2025 09:58 ET (14:58 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2508144212"}